BNET Industries
Last Fiscal Year Sales:$750.0K
- Private
- US
Dow Jones Description
Flamel Technologies is a drug delivery company with expertise in polymer chemistry. The company was founded in 1990. In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq. The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns cGMP pharmaceutical production facility of over 100,000 square feet located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules). Flamel's drug delivery platforms, Medusa for therapeutic proteins and peptides, and Micropump for small molecules , have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs. The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners. Flamel has partnership agreements with major pharmaceutical companies:
Chief Executive Officer
Stephen H WillardNumber of Employees 2
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to...
-
xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 4, 2009 : FLML, XING, AFFY and MOCO
-
Flamel Technologies Announces Second Quarter 2009 Results; Multiple New Projects; Cash Increases from $39.1 to...
News & Analysis
Filter by
flamel technologies - All News and Analysis
Flamel Technologies SA Q3 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. Our first question comes from Peter Butler of Glen Hill Investments. Please go ahead. Peter Butler - Glen Hill Investments I think you first mentioned, the commercial target dates for several molecules in a road show presentation in Boston, and I think since...
Flamel Technologies S.A. Q2 2009 Earnings Call Transcript
Flamel Technologies S.A. FLML Q2 2009 Earnings Call Transcript August 6, 2009 8:30 am ET
Flamel Technologies S.A. Q2 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. We will now begin the question-and-answer session. Operator instructions We will pause momentarily to assemble our roaster. Our first question comes from Matt Kaplan of Ladenburg Thalmann. Please go ahead. Lisa - Ladenburg Thalmann Hi, this is Lisa [ph] now. I’m sitting in on the...
Flamel Technologies SA Q1 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. Our first question comes from Matt Kaplan from Ladenburg. Please go ahead. Matt Kaplan - Ladenburg Just following up on some of your prepared remarks, can you talk a little bit about the visibility you have in terms of the transitioning of some...
Flamel Technologies S.A., Q4 2008 Earnings Call Transcript
Question-and-Answer Session Operator Thank you. We will now begin the question-and-answer session. Operator Instructions. Your first question comes from the line of Matt Kaplan of Ladenburg Thalmann. Matthew Kaplan - Ladenburg Thalmann Hi, Steve. Good morning. Stephen Willard Good morning, Matt. How are you? Matthew Kaplan -...
A Renewed Interest in Nanotechnology
Perry Sadorsky submits: A recent article in The Economist (August, 2, 2008, page 54) describes how Russia is trying to build a high technology economy. By designating the city of Dubna as a free economic zone a zone where Russian high technology companies can legally operate and pay lower taxes,...
Speak with other shareholders about: (OTCBB: PLRS), (NASDAQ: FLML), (OTCBB: CYCR) and (NASDAQ: ABAX) .
M2 PRESSWIRE-30 January 2007-Stockwire.com: Speak with other shareholders about: (OTCBB: PLRS), (NASDAQ: FLML), (OTCBB: CYCR) and (NASDAQ: ABAX) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:30012007 AUSTIN, TX - A very interesting indicator to look for is where the money is flowing into. We...
Flamel Technologies Announces Filing of Letter to Shareholders from Its Chairman under Form 6-K and Schedules Conference Call
LYON, France -- Flamel Technologies (NASDAQ:FLML) today announced the release of a filing with the SEC under cover of Form 6-K of a letter to shareholders by Flamel's Founder, Chairman, and C.E.O., Dr. Gerard Soula. The Form 6-K filing can be found through the SEC's Edgar system and on the...
Flamel Technologies Announces Filing of Letter to Shareholders from Independent Board Members under Form 6-K
LYON, France -- Flamel Technologies (NASDAQ:FLML) today announced the release of a filing with the SEC under cover of Form 6-K of a letter to shareholders by Flamel's independent directors. The Form 6-K filing can be found through the SEC's Edgar system and on the SEC's website at www.sec.gov...
Flamel Technologies Announces Filing of Letter to Shareholders under Form 6-K
LYON, France -- Flamel Technologies (NASDAQ:FLML) today announced the release of the filing with the SEC under cover of Form 6-K of a letter to shareholders by Gerard Soula, Flamel's Founder, Chairman, and Chief Executive Officer. The Form 6-K filing can be found through the SEC's Edgar system and...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Stephen H Willard | Chief Executive Officer |
| Christian Kalita | Directeur General Delegue Pharmacien Responsable (Chief Pharmacist) |
| Jeffery S. Vick | Chief Business Officer |
| Rafael Jorda | Chief Operating Officer, Executive Vice President, Director of Manufacturing and Development |
| Andrew Francis | Vice President Business Development |
| Catherine Castan | Director of R&D Micropump, Head of Micropump Team |
| Charles Marlio | Director of Strategic Planning and Investor Relations |
| Charles Mosseri-Marlio | Director of Strategic Planning and Investor Relations |
| David Weber | Director of Purchasing Operations |
| Katherine Hanras | Director of Innovative Technologies |
| Kenneth Lundstrom | Director of Research |
| Martine Capelle | Human Resources Director |
| Nigel McWilliam | Director, Business Development, USA |
| Remi Meyrueix | Scientific Director |
| Roger Kravtzoff | Preclinical and Early Clinical Development Director |
| Sian Crouzet | Controller, Administrative and Financial Director |
| Nicolas Flamel | |
| Raphaelle Portella | Legal Counsel, France |
| WILLIAM DEARSTYNE | Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Elie Vannier | Chairman (Chief Operating Officer of Grandvision Sa) |
| John L. Vogelstein | Director (Vice Chairman of Warburg Pincus) |
| Frederic Lemoine | Director (Chairman of the Supervisory Board of Areva) |
| Christian Trepo | Board of Directors |
| Yves Bourboulou | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Chief Executive Officer | Current |
| Flamel Technologies Incorporated | President | Former |
| Biovail Corporation | Vice President | Former |
| Shearman & Sterling Llp | Attorney | Former |
| Gibson, Dunn & Crutcher LLP | Attorney | Former |
| Yale Law School | Former | |
| Williams College | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Directeur General Delegue Pharmacien Responsable (Chief Pharmacist) | Current |
| Skyepharma, Inc. | Director of Quality | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Chairman (Chief Operating Officer of Grandvision Sa) | Current |
Jeffery Vick is our Chief Business Officer. Mr. Vick has more than 20 years experience in the business and research side of the biotechnology industry in both Europe and the US. Prior to joining Flamel, Mr. Vick was Chief Executive Officer of Silence Therapeutics. Mr Vick previously held senior management positions with Centelion SAS, a wholly-owned subsidiary of Aventis, Genset SA, Cytovia, Inc, and DepoTech Corporation and worked with Sanderling Venture Capital for two years. Mr Vick holds an MBA from Stanford, an MS Chemistry from the University of California, San Diego, and a BS Chemistry from the University of Virginia.
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Chief Business Officer | Current |
| Stanford University | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Chief Operating Officer, Executive Vice President, Director of Manufacturing and Development | Current |
| Virginia Polytechnic Institute and State University | Masters In Chemical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Vice President Business Development | Current |
| Skyepharma, Inc. | Group Vice President for Business Development | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director of R&D Micropump, Head of Micropump Team | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director of Strategic Planning and Investor Relations | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director of Strategic Planning and Investor Relations | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director of Purchasing Operations | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Warburg, Pincus, LLC | Managing Director, New York | Current |
| Warburg Pincus, LLC | Vice Chairman & Managing Director | Current |
| Flamel Technologies Incorporated | Director (Vice Chairman of Warburg Pincus) | Current |
| New York University | Trustee | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| New Providence Asset Management Limited | Chairman | Current |
| Prep,Inc. | Chairman of the Board of Directors | Current |
| Journal Register Company | Board of Directors | Current |
| The Jewish Museum | Board of Directors | Current |
| Sharegift USA | Board of Directors | Current |
| New York City Ballet | Director | Current |
| Warburg, Pincus, LLC | Vice Chairman, New York | Current |
| NYU Stern School of Business | Vice Chairman | Current |
| Piedmont Natural Gas Company, Inc. | Vice Chairman | Current |
| Flamel Technologies, S.A. | Board of Directors | Current |
| Americans for Gun Safety | Board of Directors | Current |
| Ags Foundation | Board of Directors | Current |
| Congregation Emanu-El | Board of Directors | Current |
| Third Way | Board of Directors | Current |
| The Jewish Museum | Trustee | Current |
| Congregation Emanu-El | Trustee | Current |
| Third Way | Trustee | Current |
| Lazard Ltd. | Partner | Former |
| Mattel, Inc. | Board of Directors | Former |
| Information Holdings Inc. | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director of Innovative Technologies | Current |
Kenneth Lundstrom joined Flamel in June 2006 as Director of Research. Dr. Lundstrom is a molecular biologist by training and has acquired a broad expertise in protein expression, viral vectors, gene therapy, structural genomics and drug delivery. He has published more than 200 peer-reviewed research articles, reviews and book chapters. Previously, Dr. Lundstrom has worked for both big pharmaceutical companies and start-up biotechnology enterprises.
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director of Research | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Human Resources Director | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director, Business Development, USA | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| University of Dundee | Bachelors Degree In Science | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Scientific Director | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| RhOne-Poulenc | Former |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Preclinical and Early Clinical Development Director | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Controller, Administrative and Financial Director | Current |
| Flamel Technologies Incorporated | Principal Financial Officer | Current |
The story of this alchemist, as handed down by tradition, and enshrined in the pages of Lenglet du Fresnoy, is not a little marvelous. He was born at Pontoise of a poor but respectable family, at the end of the thirteenth, or beginning of the fourteenth, century. Having no patrimony, he set out for Paris at an early age, to try his fortune as a public scribe. He had received a good education, was well skilled in the learned languages, and was an excellent penman. He soon procured occupation as a letter-writer and copyist, and used to sit at the corner of the Rue de Marivaux, and practice his calling: but he hardly made profits enough to keep body and soul together. To mend his fortunes he tried poetry; but this was a more wretched occupation still. As a transcriber he had at least gained bread and cheese; but his rhymes were not worth a crust. He then tried painting with as little success; and as a last resource, began to search for the philosopher's stone, and tell fortunes. This was a happier idea; he soon increased in substance, and had wherewithal to live comfortably. He, therefore, took unto himself his wife Petronelle, and began to save money; but continued to all outward appearance as poor and miserable as before. In the course of a few years, he became desperately addicted to the study of alchemy, and thought of nothing but the philosopher's stone, the elixir of life, and the universal alkahest. In the year 1257, he bought by chance an old book for two florins, which soon became the sole study and object of his life. It was written with a steel instrument upon the bark of trees, and contained twenty-one, or as he himself always expressed it, three times seven, leaves. The writing was very elegant and in the Latin language. Each seventh leaf contained a picture and no writing. On the first of these was a serpent swallowing rods; on the second, a cross with a serpent crucified; and on the third, the representation of a desert, in the midst of which was a fountain with serpents crawling from side to side. It purported to be written by no less a personage than "Abraham, patriarch, Jew, prince, philosopher, priest, Levite, and astrologer;" and invoked curses upon any one who should cast eyes upon it, without being a priest or a scribe. Nicholas Flamel never thought it extraordinary that Abraham should have known Latin, and was convinced that the characters on his book had been traced by the hands of that great patriarch himself. He was at first afraid to read it, after he became aware of the curse it contained; but he got over that difficulty by recollecting that, although he was not a priest, he had practiced as a scribe. As he read he was filled with admiration, and found that it was a perfect treatise upon the transmutation of metals. All the process was clearly explained; the vessels, the retorts, the mixtures, and the proper times and seasons for the experiment. But as ill-luck would have it, the possession of the philosopher's stone or prime agent in the work was presupposed. This was a difficulty which was not to be got over. It was like telling a starving man how to cook a beefsteak, instead of giving him the money to buy one. But Nicholas did not despair; and set about studying the hieroglyphics and allegorical representations with which the book abounded. He soon convinced himself that it had been one of the sacred books of the Jews, and that it was taken from the temple of Jerusalem on its destruction by Titus. The process of reasoning by which he arrived at this conclusion is not stated. From some expression in the treatise, he learned that the allegorical drawings on the fourth and fifth leaves, enshrined the secret of the philosopher's stone, without which all the fine Latin of the directions was utterly unavailing. He invited all the alchemists and learned men of Paris to come and examine them, but they all departed as wise as they came. Nobody could make anything either of Nicholas or his pictures; and...
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Legal Counsel, France | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Director (Chairman of the Supervisory Board of Areva) | Current |
| Flamel Technologies Incorporated | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Flamel Technologies Incorporated | Board of Directors | Current |
| Pharmacia Corporation | Manager | Former |
| Organization | Position | Status |
|---|---|---|
| Phonak AG | Member | Current |
| Flamel Technologies Incorporated | Member | Current |
| Earlybird LLC | Advisor | Current |
| Earlybird LLC | Board of Directors | Current |
| Johnson & Johnson | Company Group Chairman | Former |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes


